Jade Biosciences News and Activities

Jade Biosciences is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Jade Biosciences is a company listed under the stock ticker JBIO (US).

Acquisition, funding and merger involving Jade Biosciences.

• Jade Biosciences and Aerovate Therapeutics have announced they will merge  (posted on April 30 2025)..
• Jade Biosciences has just announced a $95 Million fundraising (posted on November 7 2024).

View the org chart displaying its 15 main executives

Most searched biographies at Jade Biosciences

• Tom Frohlich, Chief Executive Officer and Director
• Chris Cain, Director
• Eric Dobmeier, Chairman of the Board

Popular executive movements at Jade Biosciences

• Brad Dahms has joined the company as Chief Financial Officer  (posted on July 1 2025).
• Hetal Kocinsky has joined the company as Chief Medical Officer  (posted on November 7 2024).
• Tom Frohlich has joined the company as Chief Executive Officer and Director  (posted on November 7 2024).

Click here to view some more movements at Jade Biosciences

Create your alert
to follow the executive moves at Jade Biosciences.

Jade Biosciences has 2,351 competitors including Incyte (United States (USA)), Anthos Therapeutics (United States (USA)) and Valneva (France).

Popular M&A news in Biotechnology

• Renasant Bio has just announced a $54 Million fundraising (posted on July 15 2025).
• Illimis Therapeutics has just announced a $42 Million fundraising (posted on July 14 2025).
• Nuclidium has just announced a $99 Million fundraising (posted on July 14 2025).

Popular contacts in Biotechnology

• Jasbir Seehra - Chief Executive Officer and Chairman of the Board at Keros Therapeutics
• Andrea Jackson - Director at Ultivue
• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships at WIRB-Copernicus Group

Learn more about the Biotechnology industry

Press releases by Jade Biosciences

• Jade Biosciences to Participate in Upcoming Investor Conferences - Jade Biosciences
• Jade Biosciences Appoints Tom Frohlich as Chief Executive Officer and Hetal Kocinsky as Chief Medical Officer; Forms Board of Directors and Expands Financing to $95 Million - Jade Biosciences
• Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement - Jade Biosciences
• Press Release Archives - Jade Biosciences
• Jade Biosciences Launches with $80 Million to Develop Transformative Therapies for Autoimmune Diseases - Jade Biosciences

Social media about Jade Biosciences

• Jade Biosciences on Wikipedia, Google News & Yahoo Finance
• Jade Biosciences on LinkedIn, Twitter & YouTube